The global brand-name pharmaceutical industry could see revenue grow by 2% to 3% next year, according to a new report from Fitch Ratings. Uptake of new drugs and strong growth in emerging markets will partly offset modest losses as patents expire. European cost containment regulations and a weak U.S. employment market also pose challenges. Expiring patents in 2014 will be "manageable," but cost-reduction measures designed to address market challenges will likely continue, the report said.
Published in Brief: